Provexis and DSM unveil Fruitflow tie-up

UK-based research and development outfit Provexis — the only company to boast an Article 13.5 health claim approval — has signed a letter of intent to license its Fruitflow blood health ingredient exclusively to DSM Nutritional Products.

The agreement was described by Provexis as a "framework" for the development of a long-term profit-share agreement that would see Netherlands-based DSM market Fruitflow as an ingredient "in all formats in all territories."

Fruitflow is a tomato extract which has been shown to reduce the aggregation of platelets in the blood, which can prevent unwanted clotting and reduce the risk of heart disease, stroke and thrombosis.

In December, the ingredient was subject to the first Article 13.5 health claim to be written into law by the European Commission under the EU's Nutrition & Health Claims Regulation. The approved claim is: "Helps maintain normal platelet aggregation, which contributes to healthy blood flow."

Provexis said that under the agreement with DSM it would continue to "support the development of current and future formats of Fruitflow," while DSM would "contribute with its manufacturing and selling experience and excellence to a successful commercialisation of Fruitfflow." Provexis warned the letter of intent was not binding but added that it was confident a formal agreement would result from it.

Stephen Moon, CEO of Provexis, said: "We firmly believe that the expertise, scale and reputation of DSM will underpin the commercial success of Fruitflow. DSM has existing relationships with key companies globally in food, beverage and consumer healthcare. This coupled with its substantial sales force made this the best strategic fit for Provexis and will enable us to build Fruitflow into a significant global functional food brand."

Meanwhile, Provexis has unveiled the results of a clinical human trial comparing the effectiveness of Fruitflow with aspirin. Undertaken at the Rowett Institute of Nutrition and Health, part of the University of Aberdeen, the trial compared the effects of Fruitflow and aspirin in inhibiting platelet aggregation via three biological pathways.

The study found (Provexis's own words):

  • that Fruitflow showed up to 30% reduction from baseline platelet aggregation in each of three different biological pathways
  • that a single dose of aspirin caused up to 60% reduction in a single pathway, with lesser effects on the other two
  • no negative interactions between Fruitflow and aspirin when consumed together.

Provexis said the results were "significant and serve to demonstrate the potential effectiveness of Fruitflow as a preventative measure in cardiovascular health through inhibiting platelet aggregation, with no side effects." Moon added: "We are delighted with the results of this latest human trial, which highlight the substantial effect that Fruitflow can have on platelet aggregation, without the associated side effects known to occur with aspirin."

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.